63491-89-4

Upstream product

• 696-60-6 4-aminomethylphenol 

Downstream Products

• 1313042-26-0 tert-butyl N-[(3-bromo-4-hydroxyphenyl)methyl]carbamate 
• 1313040-48-0 (4-aminomethyl-2-{1-[1-(2-methoxy-ethyl)-7-methyl-1H-indole-3-carbonyl]-piperidin-4-yl}-phenoxy)-acetic acid hydrochloride 
• 1313040-47-9 2-(4-aminomethyl-2-{1-[1-(2-methoxy-ethyl)-7-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-phenoxy)-acetamide hydrochloride 
• 1313042-50-0 (4-carbamoylmethoxy-3-{1-[1-(2-methoxy-ethyl)-7-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-carbamic acid tert-butyl ester 
• 1313042-48-6 (4-carbamoylmethoxy-3-pyridin-4-yl-benzyl)-carbamic acid tert-butyl ester 
• 1313042-47-5 (3-bromo-4-carbamoylmethoxy-benzyl)-carbamic acid tert-butyl ester 
• 1313040-46-8 2-(4-aminomethyl-2-{1-[1-(2-methoxy-ethyl)-7-methyl-1H-indole-3-carbonyl]-piperidin-4-yl}-phenoxy)-acetamide hydrochloride 
• 1313042-46-4 (4-carbamoylmethoxy-3-{1-[1-(2-methoxy-ethyl)-7-methyl-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-carbamic acid tert-butyl ester 
• 1313042-49-7 (4-carbamoylmethoxy-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester 
• 1313040-44-6 2-(4-aminomethyl-2-{1-[1-(2-methoxy-ethyl)-7-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-phenoxy)-N,N-dimethyl-acetamide hydrochloride 
• 1313042-42-0 (4-dimethylcarbamoylmethoxy-3-{1-[1-(2-methoxy-ethyl )-7-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-benzyl)-carbamic acid tert-butyl ester 
• 1313040-43-5 2-(4-aminomethyl-2-{1-[1-(2-methoxy-ethyl)-7-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-phenoxy)-N-methyl-acetamide hydrochloride 
• 1313042-41-9 (3-{1-[1-(2-methoxy-ethyl)-7-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-4-methylcarbamoylmethoxy-benzyl)-carbamic acid tert-butyl ester 
• 1313042-40-8 (4-(tert-butoxycarbonylamino-methyl)-2-{1-[1-(2-methoxy-ethyl)-7-trifluoromethoxy-1H-indole-3-carbonyl]-piperidin-4-yl}-phenoxy)-acetic acid 

Relevant academic research and scientific papers

ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS

The present invention discloses and claims a series of substituted spiropiperidine benzylamines of formula (I) wherein R is as described herein. More specifically, the compounds of this invention are inhibitors of β-tryptase and are, therefore, useful as

INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS

The present invention discloses and claims a series of substituted indolyl-piperidinyl benzylamines of formula (I), wherein R1, R2 and R3 are as described herein. More specifically, the compounds of this invention are inhibitors of β-tryptase and are, therefore, useful as pharmaceutical agents. Additionally, this invention also discloses methods of preparation of substituted indolyl-piperidinyl benzylamines. In one of the embodiments, there is provided the compounds of formula (I) wherein R3 is (II).